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Submitted Jul 2, 2012; accepted Sep 18, 2012.DISCUSSIONDr John Ricotta (Washington, DC). The follow-up would
seem to me to be likely different between the two groups in terms
of the years of follow-up. One of the issues with endovascular
revascularization is late occlusion. I saw the mortality rate, the
late mesenteric-related mortality rate, but do you have any idea
about timing of occlusions in the open and the endovascular
groups and what the different follow-up for the open and the
endovascular groups were?
Dr Gustavo S. Oderich. That’s a very good question. The
average follow-up for this study was 47 months. In general, adher-
ence to follow-up was better for the endovascular group, perhaps
because these patients represented the more contemporary experi-
ence. Similar to what has happened in the United States, we have
shifted the paradigm of treatment at the Mayo Clinic around 2002
and since then, approximately 70% of the patients are treated endo-
vascularly and 30% by open surgery.
In terms of time for recurrence, Dr Ricotta, that averages 6 to
8 months. This is the topic of a recent publication at the Journal of
Vascular Surgery looking at reinterventions after mesenteric stent-
ing. We continue to recommend surveillance with duplex ultra-
sound after the initial intervention, so some of the restenoses are
detected still in the asymptomatic phase by duplex ultrasound.
However, most patients with recurrent symptoms present on
average 6 to 8 months after the procedure.
Dr Ricotta. Can you tell us, perhaps, what you would do now
in terms of selection for open repair and how many of your
patients–I know this is not the subject of this topic, but I know
you’ve reported on it before – how many of your patients had total
occlusions versus stenoses?
Dr Oderich. Well, the reasoning behind this study was really
the lack of data in terms of late death from mesenteric-related
causes after a mesenteric revascularization. And, there was
a concern that the endovascular group could have late mesenteric
thrombosis because of the higher restenosis rates. This study has
shown that this is not the case.In terms of selection, the anatomy of the SMA is probably the
most important factor rather than the clinical risk as used in the
past. We still feel that in patients with extensive SMA disease,
long occlusions, or severely calciﬁed lesions, open surgery is an
excellent choice particularly if the patient is low or intermediate
risk. It’s probably one of the nicest operations that we do. We
like to do it with a supraceliac bifurcated graft with two-vessel
reconstruction. And, we have shown that this can be done with
low mortality rates in the low-risk group. If the SMA lesion is
favorable, we stent regardless of the clinical risk, but it is important
to discuss with the patient surveillance and the need for reinterven-
tion for symptomatic restenosis.
Dr Juan Parodi (Buenos Aires, Argentina). I have a question
related to the endo treatment. Have you seen fractures of the
stents due to the mobility of the SMA?
DrOderich.Dr Parodi, we have not seen fractures in the stents.
I have to say perhaps we haven’t looked at it that carefully on the
aspect of fractures. I have seen it occur with celiac axis stents due to
compressionby themedian arcuate ligament.Wehave seen, however,
that in many patients with restenosis, the result of the initial interven-
tion is often not optimal, with missed lesions, partially compressed
stents. We found that a suboptimal result at the initial intervention
is a major cause of residual stenosis leading to reintervention.
Dr Kenneth Madsen (Cheyenne, Wyo). My two questions:
1. What medical therapy do you have these people on? Do you
do aspirin and Plavix therapy?
2. Do you have any idea what percentage of these people are
adequately followed with duplex and what percentage actually
need something like MRA or CTA?
Dr Oderich. Medical therapy has improved greatly in the last
decade compared to the 1990s, which is reﬂected by the higher
number of patients on statins and antiplatelet therapy. For the
most part, all the patients are on antiplatelet therapy. Our standard
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lowed by aspirin. If we use a covert stent, we tend to keep these
patients on clopidogrel permanently.
Dr Piergiorgio Cao (Rome, Italy). My question is related to
your methodology. You wrote in the abstract, and the speakers
tell us, that you used propensity score to make the two groups
comparable, endo versus open. There is serious imbalance between
the two groups with regard to the type of population and riskfactors. How was the sample size of the two groups reduced after
application of the propensity-score analysis? This can inﬂuence
any comparison between the two groups.
Dr Oderich.Well, this is a great question and to be frank with
you, I’m not the most qualiﬁed person to answer because we did
rely on our statistician Mr Steve Cha to help with this analysis.
In short, 80% of the patients were analyzed using the propensity
score-matched comparison.
